NCT07234474尚未招募1 期
A Phase I Study of YK012, a Humanized CD19 × CD3 Bispecific Antibody, in Participants With Very High-Risk, Refractory Primary Membranous Nephropathy
Excyte Biopharma Ltd0 个研究点目标入组 66 人开始时间: 2026年10月1日最近更新:
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 66
- 主要终点
- Ia: Dose-Limiting Toxicity (DLT)
研究概览
简要总结
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics(PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of YK012 in participants with primary membranous nephropathy (pMN).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18-80 (inclusive), both gender.
- •Diagnosed with primary (idiopathic) membranous nephropathy by renal biopsy within 10 years.
- •Participants who meet the criteria of very high-risk primary (idiopathic) membranous nephropathy based on 2021 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Glomerular Diseases and who have failed available therapies for the treatment of pMN.
- •eGFR estimated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula is ≥45 mL/min/1.73 m².
- •If taking angiotensin-converting enzyme inhibitor (ACEI), angiotensin II receptor blocker (ARB), or Sodium-Glucose Co-Transporter 2 (SGLT-2) inhibitor, the medication dosage must have been stable (≤50% change in dose) for at least 4 weeks prior to screening and continue being stable prior to the initiation of the investigational product.
- •Laboratory tests within 7 days prior to enrollment meet the pre-defined criteria.
- •Be able to understand and voluntarily participate in this clinical trial with written signed informed consent and available for scheduled visits, treatments, examinations, and other study procedures.
排除标准
- •Diagnosed with secondary membranous nephropathy.
- •Any prior receipt of protocol-specified pharmacological treatment for membranous nephropathy.
- •History of malignant tumor within 5 years prior to screening.
- •Poorly controlled hypertension.
- •Participants with severe renal insufficiency who have received or require dialysis or kidney transplantation within 6 months prior to the initiation of the investigational product.
- •History of diabetic nephropathy confirmed by renal biopsy.
- •History of severe or chronic infections within 6 months prior to screening or currently infection requiring systemic antibiotic or antiviral therapy.
- •History of cardiovascular event leading to hospitalization within 6 months prior to screening.
- •Other severe or poorly controlled diseases that may affect the protocol compliance or efficacy assessments.
- •Have active tuberculosis with clear evidence of infection.
- •History of substantial organ or bone marrow transplantation.
- •Received live vaccination, underwent major surgery, or participated in other clinical trials and applied any other study drugs within 28 days prior to the initiation of the investigational product.
- •Hepatitis B surface antigen (HBsAg) positive, or hepatitis B core antibody (HBcAb) positive with hepatitis B virus (HBV) DNA quantification ≥ 1×103 copies/L or ≥ 50 IU/L (HBcAb positive participants require regular HBV DNA testing); Hepatitis C virus (HCV) antibody positive; Human immunodeficiency virus (HIV) seropositive; Syphilis helical antibody positive.
- •Peripheral blood CD4+ T-lymphocyte count < 200 cells/μL.
- •The peripheral blood B-cell count is below the lower limit of normal.
- •Known hypersensitivity to any of the ingredients of YK
- •Female participants who are pregnant or breastfeeding, or women of childbearing potential (WOCBP) who have a positive pregnancy test result at screening; or those who plan to have children during the trial period and for 12 months after the end of the trial, and those who are unwilling to use one or more physical contraceptive methods during the trial period and for 12 months after the end of the trial.
- •Other conditions that the investigator considers inappropriate for participation in this trial.
研究组 & 干预措施
Ia: YK012
Experimental
Participants with primary membranous nephropathy will receive ascending doses of YK012 infusion to evaluate the safety and tolerability of YK012, and to determine the Maximum Tolerated Dose (MTD) and Recommended Dose for Expansion (RDE)
干预措施: YK012 (Drug)
Ib: YK012
Experimental
Participants will receive 2 different doses of YK012 infusion to evaluate the safety and tolerability of YK012 in participants with primary membranous nephropathy and to establish the Recommended Phase II Dose (RP2D).
干预措施: YK012 (Drug)
结局指标
主要结局
Ia: Dose-Limiting Toxicity (DLT)
时间窗: up to 28 days after the first dose
Adverse Event (AE)
时间窗: From the first induction to the end of the trial at 53 weeks
Severe Adverse Event
时间窗: From the first induction to the end of the trial at 53 weeks
次要结局
- Area under the concentration-time curve (AUC0-t)(From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks)
- Area under the concentration-time curve from time 0 to ∞ (AUC0-∞)(From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks)
- Maximum plasma concentration (Cmax)(From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks)
- Time to reach maximum concentration (Tmax)(From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks)
- Half-life (t1/2)(From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks)
- Apparent clearance (CL)(From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks)
- apparent volume of distribution (Vd)(From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks)
- Minimum plasma concentration (Cmin)(From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks)
- Time to onset and duration of peripheral blood B-cell and B-cell subset depletion(From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks)
- Changes in peripheral blood Natural Killer (NK) cells(From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks)
- Changes in peripheral blood T cells and T cell subsets (CD4+ T cells, CD8+ T cells)(From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks)
- The profile of cytokine changes(From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks)
- Positive rates of blood anti-drug antibody (ADA) and neutralizing antibody (Nab)(From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks)
- Changes from baseline in 24-hour urine protein during the trial period(From screening to the end of the trial at 53 or 77 weeks)
- Changes from baseline in estimated glomerular filtration rate (eGFR) during the trial period(From screening to the end of the trial at 53 or 77 weeks)
- Changes from baseline in anti-phospholipase A2 receptor (PLA2R) antibody titer during the trial period(From screening to the end of the trial at 53 or 77 weeks)
- Proportion of participants achieving overall renal remission (ORR)(From screening to the end of the trial at 53 or 77 weeks)
- Proportion of participants achieving Complete Response (CR) and Partial Response (PR)(From screening to the end of the trial at 53 or 77 weeks)
- Proportion of participants achieving immunological remission(From screening to the end of the trial at 53 or 77 weeks)
- Time to achieve CR(From screening to the end of the trial at 53 or 77 weeks)
- Time to achieve ORR(From screening to the end of the trial at 53 or 77 weeks)
- Duration of CR(From screening to the end of the trial at 53 or 77 weeks)
- Duration of ORR(From screening to the end of the trial at 53 or 77 weeks)
- Proportion of participants with treatment failure(From screening to the end of the trial at 53 or 77 weeks)
- Proportion of participants who relapsed(From screening to the end of the trial at 53 or 77 weeks)
研究者
相似试验
已完成
1 期
Evaluating the Safety and Pharmacokinetics of VRC07-523LS in the Sera and Mucosae of Healthy, HIV-Uninfected Adult ParticipantsHIV InfectionsNCT03735849National Institute of Allergy and Infectious Diseases (NIAID)28
招募中
1 期
A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD ParticipantsSystemic Lupus ErythematosusNCT06576271GlaxoSmithKline142
已完成
1 期
To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of KP104Paroxysmal Nocturnal HemoglobinuriaNCT05490017Kira Pharmacenticals (US), LLC.80
已完成
1 期
First Time in Human Study of ProtexiaIntervention for Nerve Agent ExposureNCT00744146PharmAthene, Inc.33
招募中
1 期
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple MyelomaPlasma Cell DisorderMultiple MyelomaNCT04879043Heidelberg Pharma AG78